Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

• Hoofdauteurs: R. Caporali (Auteur), M. Filippini (Auteur), R. Gorla (Auteur), E.G. Favalli (Auteur), A. Marchesoni (Auteur), M. Antivalle (Auteur), P. Sarzi- Puttini (Auteur), F. Bobbio-Pallavicini (Auteur), C. Montecucco (Auteur), F. Atzeni (Auteur)
• Formaat: Boek
• Gepubliceerd in: PAGEPress Publications, 2011-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treati...